The Department of Defense Prostate Cancer Research Program is pre-announcing the application process for its funding awards even though due to the current Continuing Resolution, the Fiscal Year 2017 Defense Appropriations bill has not been passed to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
